Kewaunee Scientific Corporation — Form 10-K Summary
Reporting period: Fiscal year ended April 30, 2014. The request identifies 2013 Q4, but the filing is an annual report for fiscal 2014; fourth-quarter data are presented below where relevant.
Business Context
Kewaunee designs, manufactures, and installs laboratory, healthcare, and technical furniture, including cabinetry, fume hoods, workstations, casework, and related systems. Operations are reported as Domestic and International. Products are sold through dealers, commissioned agents, a national distributor, competitive bids, and subsidiaries in Singapore, India, and China.
The business is competitive and tied to laboratory, healthcare, and construction activity. Customer project delays can defer shipments and revenue recognition, while firm-price contracts expose the company to labor, material, energy, and installation-cost increases.
Key Financial Metrics
| Metric | FY2014 | FY2013 | Change |
|---|---|---|---|
| Net sales | $111.2 million | $117.1 million | Down 5.1% |
| Gross profit | $22.0 million | $22.3 million | Down 1.0% |
| Gross margin | 19.8% | 19.0% | Up 0.8 percentage points |
| Operating earnings | $6.0 million | $5.3 million | Up 13.0% |
| Net earnings attributable to Kewaunee | $3.9 million | $3.0 million | Up 28.0% |
| Diluted earnings per share | $1.48 | $1.17 | Up $0.31 |
| Cash dividends per share | $0.44 | $0.40 | Increased |
| Operating cash flow | $8.1 million | $3.8 million | Up $4.2 million |
Domestic sales were $91.8 million, down 2%, while International sales were $19.4 million, down 18%. The international decline primarily reflected a delayed shipment of a large order.
Fourth-quarter fiscal 2014 sales were $27.1 million, gross profit was $5.9 million, net earnings were $1.0 million, and diluted earnings per share were $0.37. Fourth-quarter fiscal 2013 sales were $31.8 million, gross profit was $6.8 million, net earnings were $1.4 million, and diluted earnings per share were $0.46.
Balance Sheet, Debt, and Liquidity
- Cash and cash equivalents were $6.2 million at April 30, 2014, compared with $5.8 million at April 30, 2013.
- Working capital was $27.2 million, compared with $25.1 million; the current ratio improved to 2.7-to-1.0 from 2.1-to-1.0.
- Total borrowings were $7.8 million, compared with $10.5 million, including $2.9 million drawn on a $20 million revolving credit facility.
- The company had $12.8 million of unused and available revolving credit capacity and $4.3 million of outstanding letters of credit.
- Capital expenditures were $2.0 million, compared with $2.4 million.
- Total assets were $62.7 million and Kewaunee stockholders’ equity was $34.0 million.
Operating activities generated $8.1 million, primarily from earnings and reductions in receivables and inventory. Financing activities used $5.5 million, including debt repayment, dividends, and $1.8 million paid toward the purchase of the remaining minority interest in Kewaunee Labway Asia.
Material Changes Versus the Prior Period
- Sales declined because of a domestic shift toward dealer-supplied project management and installation services and an international order-shipment delay.
- Gross margin improved because of a more favorable product mix.
- Operating expenses declined to $16.1 million from $17.0 million, including a $425,000 reduction in corporate salary and benefit costs.
- Net earnings attributable to Kewaunee increased despite lower sales, supported by improved margins, lower operating expenses, and reduced earnings allocated to noncontrolling interests.
- The company purchased the remaining 49% minority interest in Kewaunee Labway Asia for $3.6 million, increasing ownership to 100%. Remaining payments total $1.8 million, payable in two equal installments.
- Order backlog increased to $89.0 million from $80.2 million. More than 70% was expected to ship during fiscal 2015, subject to customer rescheduling and construction delays.
- The company entered into a new credit agreement in May 2013 and implemented interest-rate swaps covering portions of its long-term debt.
Guidance, Outlook, Risks, and Unusual Items
Management stated that demand is difficult to forecast because the company often acts as a subcontractor or supplier to dealers. Fiscal 2015 capital expenditures were expected to be approximately $2.3 million, primarily for manufacturing equipment, funded mainly through operations and, if necessary, revolving-credit borrowings. Management believed available liquidity would support ongoing requirements through fiscal 2015.
- Key risks include construction-project delays, customer order rescheduling, competitive bidding and pricing pressure, and volatility in laboratory construction activity.
- Firm-price contracts expose margins to increases in steel, stainless steel, wood, epoxy resin, labor, and energy costs.
- The national stocking distributor represented approximately 9% of fiscal 2014 sales, while two domestic dealers represented approximately 24%; combined sales to these three customers were approximately 33%.
- International operations create exposure to foreign exchange, political and regulatory conditions, tariffs, freight costs, and local market acceptance.
- The defined-benefit pension plan remained underfunded by $3.6 million at April 30, 2014. No pension contribution was anticipated for fiscal 2015, although estimated pension payments and future expense remain relevant.
- Contractual cash obligations totaled $13.2 million, including $6.9 million of operating leases, $4.6 million of long-term debt, and $1.8 million related to the minority-interest purchase.
- Pending ordinary-course litigation and government audits were not expected by management to have a material adverse effect. Management reported effective disclosure controls and internal control over financial reporting.
Investor Verification Checklist
- Verify whether the $89.0 million backlog converted into shipments and revenue during fiscal 2015.
- Assess the sustainability of margin improvement, particularly against raw-material and labor-cost inflation.
- Review customer concentration and the impact of dealer-channel changes on reported sales and margins.
- Confirm available revolving-credit capacity, letters of credit, financial-covenant compliance, and interest-rate swap terms.
- Monitor international sales recovery after the delayed large-order shipment and the effect of foreign exchange movements.
- Review pension funding requirements, actuarial assumptions, and the remaining minority-interest purchase payments.
- Note that the filing contains no formal revenue or earnings guidance beyond the disclosed capital-expenditure expectation and liquidity assessment.